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CI-994 (acetyldinaline)is an investigational anticancer drug currently in clinical trials. In preclinical safety studies in rats and dogs,
CI-994 resulted in signiﬁcant toxicity to bone marrow and lymphoid tissue. To determine if apoptosis was involved in CI-994
toxicity, peripheral blood lymphocytes were isolated from untreated male Wistar rats and exposed to CI-994 (1, 3, 10, or 30µM) in
vitro for up to 24hours. Morphological and biochemical features of apoptosis were evaluated using several techniques, and lactate
dehydrogenase (LDH)release was measured as an indicator of cell necrosis. No evidence of apoptosis or necrosis was detected in
lymphocytes exposed to CI-994 for 4hours. After 24hours, concentration-dependent increases in apoptosis characterized by DNA
condensation,DNAfragmentation,and/orexternalizationof phosphatidylserinewereseenatCI-994concentrationsaslowas1µM
and were statistically signiﬁcant beginning at 10µM. Ultrastructural analysis conﬁrmed the presence of DNA condensation, DNA
fragmentation, cell shrinkage, and membrane blebbing in cells exposed to 30µM CI-994. After 24hours, the percent of maximum
LDH release from lymphocytes treated with 10 and 30µM CI-994 was 7% and 15%,respectively,compared with 0% in the controls.
Incomparison,morphologicalchangesof apoptosisdetectedbyﬂuorescentmicroscopywereobservedin79%of thelymphocytesat
thesetwoconcentrations.Additionally,apoptosiswasseeninmorethan24%of lymphocytesexposedto1and3µMCI-994,whereas
maximum LDH release was less than or equal to 1% at these concentrations. These results show that apoptosis is the primary mode
of cell death in rat lymphocytes exposed to CI-994 in vitro.
INTRODUCTION
CI-994 (acetyldinaline; Figure 1)is an investigational an-
ticancerdrugwithactivityinabroadspectrumof mouse,rat,
and human tumor models [1–5]. CI-994 can also potentiate
the activity of other standard chemotherapeutic agents. For
example, simultaneous administration of CI-994 and gem-
citabine results in greater than additive activity in a preclini-
calmodelof squamouscelllungcarcinoma[6].Althoughthe
mechanism of action of CI-994 is unknown, it appears to be
novel when compared with other existing anticancer agents.
CI-994 is not an antimetabolite, does not covalently bind to
orintercalateDNA,anddoesnotaffectmicrotubulesynthesis
[7]. Studies have shown that CI-994 can inhibit a 16kDa nu-
clear phosphoprotein and increase histone acetylation [8, 9].
Currently, CI-994 is in phase II clinical trials.
Despiteanunknownmechanismof action,thetoxicityof
CI-994 is similar to many other cytotoxic anticancer drugs in
that it primarily involves effects on bone marrow, lymphoid
tissue, and testes [10–13]. When CI-994 was administered
orally to Wistar rats or beagle dogs once daily for two weeks,
toxicityinbothspeciesincludedneutropenia,lymphocytope-
nia, thrombocytopenia, lymphoid depletion, bone marrow
hypocellularity,and testicular degeneration [10]. Lymphocy-
topenia and depletion of lymphoid tissue were also noted in
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Figure 1: Chemical structure of CI-994.
rats within 24hours of a single oral dose of CI-994 [11]. In
mice, neutropenia, lymphocytopenia, and thrombocytope-
nia were observed when CI-994 was administered orally for
14days [12]. Neutropenia and thrombocytopenia were also
thedose-limitingtoxicitiesof CI-994inaphaseIclinicaltrial
[13]. Collectively, these results demonstrate that peripheral
bloodlymphocytesrepresentatoxicologicallyrelevantmodel
for studying the mechanism of CI-994 toxicity in vitro.
Since myelosuppression was observed in all species and
was the dose-limiting toxicity in humans, characterizing CI-
994toxicityinhematopoieticcellsisof greatinterest.Toxicity
can lead to cell death by two distinct processes; necrosis or
apoptosis [14–18]. Necrosis is a more passive form of cell
death that is characterized by metabolic collapse resulting
from severe pathologic- or chemical-induced injury. During
necrosis, cells lose their ability to maintain osmotic balance1:2 (2001)Induction of apoptosis in rat lymphocytes by CI-994 53
due to a depletion of ATP. This, in turn, leads to swelling
of organelles and lysis of the plasma membrane. Necrosis
is often associated with extensive tissue damage and an in-
tense inﬂammatory response. Apoptosis, on the other hand,
is an active process that can occur under normal physio-
logical conditions as well as in response to chemical injury.
Apoptosisinvolvestheactivationof variouscellsignalingcas-
cades which results in characteristic morphological and bio-
chemicalchangessuchascellshrinkage,membraneblebbing,
DNAcondensation,andfragmentation.Thecelliseventually
broken down into smaller membrane-bound vesicles termed
apoptotic bodies that become engulfed by surrounding cells
without initiating an inﬂammatory response.
The objective of the present study was to investigate
whether CI-994 induced apoptosis in peripheral blood lym-
phocytes, one of the cell types depleted during CI-994 treat-
mentinvivo.Speciﬁcally,peripheralbloodlymphocyteswere
isolated from male Wistar rats and morphological and bio-
chemical features of apoptosis were assessed following incu-
bation with CI-994 for up to 24hours. Multiple techniques
wereusedinthisstudysinceitiswellrecognizedthatnosingle
assayissufﬁcientforunambiguousclassiﬁcationof apoptotic
cells[19].LDHrelease(indicatingalteredmembraneperme-
ability)was also measured as an indicator of necrosis. The
results showed that apoptosis was the primary mode of cell
death in rat lymphocytes exposed to CI-994 in vitro.
MATERIALS ANDMETHOD S
Chemicals
CI-994 (97.6% active)was synthesized at Goedecke AG
Research and Development (Freiburg, Germany). Stock so-
lutions of CI-994 were prepared in 100% ethanol and fur-
ther diluted with sterile water to achieve the appropriate test
concentrations. The intended drug concentration of each so-
lution was conﬁrmed analytically. Solutions were stored at
room temperature. All other chemicals, unless noted, were
purchased from Sigma Chemical Co. (St. Louis, MO).
Isolationandtreatmentofperipheral
bloodlymphocytes
Random-bred, male Wistar (Crl:(WI)BR) rats were ob-
tained from Charles River Laboratories (Portage, MI). An-
imals were housed individually in stainless steel cages and
were maintained in environmentally controlled rooms with
a 12h light/dark cycle. Powdered Purina Certiﬁed Rodent
Chow 5002  (Ralston Purina, St. Louis, MO)and tap wa-
t e rw e r ep r o v i d e dad libitum.Animals were acclimated to the
laboratory environment for a minimum of 7days prior to
use on study. This study was conducted according to current
guidelinesforthecareanduseof laboratoryanimals[20]and
was approved by the PﬁzerAnimal Care and Use Committee.
Clinically acceptable rats weighing more than 170g were
used on study. Animals were euthanized by carbon diox-
ide inhalation and blood samples were collected in hep-
arinized tubes by cardiac puncture. Blood was diluted in
supplemented Hank’s Balanced Salt Solution (Gibco BRL,
GrandIsland,NY)containing5%FBS(Hyclone,Logan,UT),
100U/ml penicillin, and 0.1% streptomycin (Gibco BRL)to
yield a ﬁnal volume of 24.5ml. The diluted blood samples
were layered on top of Histopaque 1077 (Ficoll/sodium dia-
trizoate)and centrifuged at 425 × g for 30minutes at room
temperature. The mononuclear cell layer was removed and
washed three times with supplemented Hank’s Balanced Salt
Solution (300×g,10minutes). Following the last wash,cells
were counted and resuspended in supplemented RPMI-1640
media (Gibco BRL), pH 6.8, containing 25mM Hepes, 10%
FBS,100U/ml penicillin,and 0.1% streptomycin to give a ﬁ-
nal concentration of 1×106 cells/ml.A ﬁxed number of cells
were added to 96-well microtiter plates (2 × 105 cells)or 6-
well microtiter plates (2×106 cells)and immediately treated
withmitogen(concanavalinA;0.63µg/mL)andCI-994(1,3,
10,or30µM).Thecellswerethenincubatedfor4or24hours
at 37◦Cin5%CO2.Anequivalentvolumeof vehicle(distilled
water)was added to the untreated (control)lymphocytes.
The amount of ethanol in the CI-994 solutions was less than
1% (v/v). Concanavalin A was added to the culture media in
the present study since preliminary experiments showed that
it had a protective effect on untreated lymphocytes by sig-
niﬁcantly reducing the spontaneous incidence of apoptosis.
Supplemental assays were also performed to determine the
effect of CI-994 on nonproliferating lymphocytes. For these
latterassays,lymphocyteswereincubatedwithCI-994(1and
30µM)for 24hours without mitogen.
Lymphocyteproliferation
Lymphocyte proliferation was determined by the addi-
tion of 0.5µCi of [3H]thymidine to each well in a 96-well
plate according to the assay conditions described above.
[3H]Thymidine was added at the time of assay initiation.
Theamountof[3H]thymidineincorporatedintolymphocyte
DNA was counted by liquid scintillation spectroscopy. Four
separate lymphocyte proliferation assays were performed.
Fluorescentmicroscopy
Lymphocytes were collected and immediately incubated
with100µg/mlacridineorangeand100µg/mlethidiumbro-
mide (in PBS)to visualize apoptotic cells. For quantitative
analysis,cellswereviewedwithanOlympusAH-3microscope
at 40 ×using FITC ﬁlter sets to excite (488nm)and visualize
(530nm)stains. Cells containing stained pycnotic nuclei
(DNA condensation)were considered apoptotic. Staining
andscoringproceduresfollowedthosedescribedinMcGahon
et al. [21]. Two to four hundred cells were counted per treat-
ment,andmeasurementswereobtainedfromatleastfourin-
dependentexperiments.Forimagecapture,cellswerestained
for DNA using Hoechst 33342 (Molecular Probes, Eugene,
OR)and mounted on standard microscope slides. Images
werecapturedusinga 100×objectivewithahigh-resolution,
liquid-cooled CCD camera (Quantix, RS-Photometrics,54 Michael J. Graziano et al. 1:2 (2001)
Tucson, AZ)mounted on an inverted ﬂuorescence micro-
scope (Axiovert 135, Zeiss, NewYork, NY). Illumination was
provided by a 100watt mercury lamp using a DAPI dichroic
ﬁlter set (Chroma Technology, Brattleboro,VT).
Electronmicroscopy
Approximately 1–2 × 106 cells were ﬁxed in 2.5% glu-
taraldehyde(Polysciences,Warrington,PA)for1h.Cellswere
then collected by centrifugation and rinsed three times in
0.1M cacodylate buffer, pH 7.4. Cells were osmicated for ap-
proximately 1h, rinsed three times in cacodylate buffer, then
dehydrated and embedded in epoxy resin. Ultrathin sections
were examined using an FEI Philips CM100 BioTWIN trans-
mission electron microscope.
FlowcytometricanalysisofDNAcontent
Lymphocytes were collected and ﬁxed in 70% ethanol for
atleast30minutes.Fixedcellswerethenstainedwith5µg/ml
Hoechst 33342 to detect total DNA within cells [22]. Sam-
ples were collected on a Coulter Epics Elite ﬂow cytometer,
anddatawereanalyzedandquantitatedusingModﬁtLT soft-
ware (Verity Software House, Inc.). Cells with sub-G1 DNA
content were considered to be apoptotic. At least four inde-
pendent experiments were performed.
DNAfragmentationassay
DNA was isolated from lymphocytes using the apoptotic
DNA-Ladder kit (Boehringer Mannheim, Indianapolis, IN).
Isolated DNA was quantitated spectrophotometrically using
SoftmaxPro2.4.1software(MolecularDynamics,Sunnyvale,
CA). DNA (0.6µg)was separated by electrophoresis on a 1%
agarose gel stained with ethidium bromide for visualization.
Results were conﬁrmed by three independent experiments.
Flowcytometricanalysisofphosphatidylserine
externalization
Lymphocytes were collected and immediately incubated
with annexin V-FITC, which binds to phosphatidyl serine
(PS)present on the outer cellular membrane. Staining was
performed using Annexin V-FITC Apoptosis Detection Kit
purchased from Oncogene Research Products (Cambridge,
MA). Procedures followed the manufacturer’s instructions.
Propidium iodide stain was included for differentiating vi-
able and nonviable (late apoptotic/necrotic)cells. Samples
were collected using the Coulter Epics Elite ﬂow cytometer,
anddatawereanalyzedandquantitatedusingWinlist4.0soft-
ware(VeritySoftwareHouse,Inc.).Cellswithincreasedgreen
stainingduetothebindingof annexinV-FITCtoPSwerecat-
egorized as apoptotic.At least four independent experiments
were performed.
Lactatedehydrogenase(LDH)releaseassay
Lymphocytes were evaluated for the presence of necrotic
cell death by measuring LDH release from cells into the cul-
ture medium. LDH release was detected using the CytoTox
96  Non-Radioactive Cytotoxicity Assay (Promega). Proce-
dures followed manufacturer’s instructions. Data were col-
lected from three independent experiments.
Statisticalanalysis
Statistical analysis was performed using SigmaStat 2.03
software (SciTech International, Inc., Chicago, IL). Differ-
enceswith p valueslessthan0.05wereconsideredstatistically
signiﬁcant.
RESULTS
Lymphocyteproliferation
Thenumberof proliferatinglymphocytesinthepresence
of concanavalinA was 1% and 4% after 4hours and 24hours
of incubation,respectively.
Morphologicalchanges
There was no signiﬁcant increase in the number of apop-
totic cells detected by ﬂuorescent microscopy after 4hours
of exposure to CI-994 (Figure 2). After 24hours of expo-
sure, the number of apoptotic lymphocytes at 10 and 30 µM
CI-994 was signiﬁcantly increased relative to the untreated
controls:79%at10and30µMCI-994versus16%inthecon-
trols(Figure2).Althoughnotstatisticallysigniﬁcant,theper-
centage of apoptotic cells was also increased at 1 and 3µM
CI-994: 28% and 34%, respectively. For lymphocytes incu-
batedwithoutmitogen,thepercentageof apoptoticcellswere
12%, 15%, and 51%, at CI-994 concentrations of 0, 1, and
30µM, respectively. Condensed chromatin, apoptotic bod-
ies, and membrane blebbing were characteristic of apoptotic
cells (Figure 3). Ultrastructural examination of rat lympho-
cytesexposedto30µMCI-994for24hoursalsoshowedtypi-
cal morphological features of apoptosis including chromatin
condensation and fragmentation, membrane blebbing, and
cell shrinkage (Figure 4).
DNAfragmentation
Apoptotic cells ﬁxed and permeabilized in ethanol lose
fragmented DNA resulting in DNA histograms with a sub-
G1 DNA content [23–25]. No signiﬁcant increase in sub-G1
cells was detected in rat lymphocytes treated with CI-994 for
4hourswhenanalyzedbyﬂowcytometryandHoechst33352
stain(Figure5).However,exposuretoCI-994for24hoursled
to a dose-related increase in the number of sub-G1 cells rela-
tive to the untreated controls (Figure 5). The increase in sub-
G1cellswasstatisticallysigniﬁcantat30µMCI-994.Without
mitogen,thepercentageofapoptoticcellsdetectedbyﬂowcy-
tometry and Hoechst 33352 stain were 18%, 15%, and 55%,
at CI-994 concentrations of 0, 1, and 30µM, respectively.
A distinct DNA fragmentation pattern consisting of multi-
ples of 180bp was also observed in rat lymphocytes exposed
to CI-994 for 24hours when analyzed by gel electrophoresis1:2 (2001)Induction of apoptosis in rat lymphocytes by CI-994 55
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Figure 2: Apoptosis in rat peripheral blood lymphocytes exposed to CI-994 for 4 or 24hours. Mitogen (concanavalin A, 0.63µg/ml)was
added to all lymphocyte cultures at time zero. Apoptotic cells characterized by condensed DNA were visualized by ﬂuorescent microscopy
and acridine orange/ethidium bromide stain. Data represent the mean ± SE of at least 4 individual experiments.
∗Signiﬁcantly different from control using Kruskal-Wallis one way ANOVA on ranked data and Dunn’s post hoc test (p<0.05).
(Figure 6). DNA fragmentation was evident at CI-994 con-
centrations as low as 3µM with a dose-related increase in
band intensity.
Membranechanges
A biochemical marker of apoptosis that does not involve
changes in DNA is redistribution of PS from the inner leaﬂet
to the outer leaﬂet of the cellular membrane [26, 27]. Using
the binding of ﬂuorescein isothiocyanate (FITC)-labeled an-
nexinV to externalized PS,apoptotic cells can be quantitated
by ﬂow cytometry [27,28]. There was no signiﬁcant increase
inthepercentoflymphocytesexhibitingexternalizationofPS
after 4hours of exposure to CI-994 (Figure 7).After 24hours
of incubation, rat lymphocytes treated with 30µM CI-994
showed a signiﬁcant increase in externalization of PS relative
to untreated controls (Figure 7). Although not statistically
signiﬁcant, the number of lymphocytes exhibiting PS exter-
nalization also appeared to be increased at 10µm CI-994.
Necroticcelldeath
No signiﬁcant increase in LDH release was detected in
the culture medium of any of the treatment groups after
4hours of exposure to CI-994. After 24hours of incubation,
Table 1:LDHreleasefromratperipheralbloodlymphocytestreated
with CI-994.
Treatment group Percent of maximum LDH releasea
4h incubation 24h incubation
Untreated 0.0 ± 0.00 .0 ± 0.0
1µM CI-994 0.0 ± 1.00 .0 ± 1.3
3µM CI-994 0.0 ± 0.40 .4 ± 1.9
10µM CI-994 1.6 ± 0.97 .0 ± 2.2∗
30µM CI-994 2.0 ± 0.71 5 .1 ± 3.5∗
Positive controlb 111.5 ± 13.6∗ 129.9 ± 14.8∗
aValues are means ± SE, n = 3.
bPositive control = NP40 cell lysis buffer.
∗Signiﬁcantly different from control using Kruskal-Wallis one way
ANOVA on ranked data and Dunn’s post hoc test (p<0.05).
a signiﬁcant increase in LDH release above control levels was
detected in the medium from lymphocytes treated with 10
and 30µM CI-994 (Table 1). For these two treatments, the
percent of maximum LDH release was 7% and 15%, respec-
tively, compared with 0% in the controls.56 Michael J. Graziano et al. 1:2 (2001)
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Figure3:Fluorescentstainingof (A)untreatedratperipheralblood
lymphocyte and (B)rat peripheral blood lymphocyte exposed to
30µM CI-994 for 24hours. Mitogen (concanavalin A, 0.63µg/ml)
was added to all lymphocyte cultures at time zero. Morphological
changes typical of apoptosis including condensed chromatin,apop-
toticbody,andmembraneblebbingareapparentintreatedlympho-
cyte.
DISCUSSION
Apoptosis is a common mechanism of cell death that is
characterized by chromatin condensation, DNA fragmenta-
tion,membrane blebbing,and cell shrinkage without altered
permeability of the plasma membrane [14–18,21,29–32]. In
contrast to apoptosis, necrosis is characterized by organelle
and cell swelling, loss of membrane integrity, rupture of the
plasma membrane,and cell lysis. In the present study,several
different techniques were used to assess apoptosis and necro-
sis in rat peripheral blood lymphocytes exposed to CI-994.
Based on changes in cell morphology, a dose-related trend
of increased apoptosis was observed at all CI-994 concen-
trations.Theeffectsat10and30µMCI-994werestatistically
signiﬁcant.Attheselatterconcentrations,almost80%oflym-
phocytes were undergoing apoptosis after 24hours. In com-
Figure4:Electronmicrographof(A)untreatedratperipheralblood
lymphocyte and (B)rat peripheral blood lymphocyte exposed to
30µM CI-994 for 24hours. Mitogen (concanavalin A, 0.63µg/ml)
was added to all lymphocyte cultures at time zero. Treated lym-
phocyte shows morphological changes of apoptosis including chro-
matin condensation and fragmentation, membrane blebbing, and
cell shrinkage.
parison, less than 15% of lymphocytes treated with 30µM
CI-994 were undergoing necrosis based on release of LDH.
These results demonstrate that necrosis plays little if any role
in the toxicity of CI-994 and that apoptosis is the primary
mechanism of cell death.
The ability of CI-994 to induce apoptosis in peripheral
bloodlymphocyteswithin24hoursinvitroisconsistentwith
the in vivo effects produced by this drug. Speciﬁcally, ad-
ministration of CI-994 to male rats caused signiﬁcant re-
ductions in lymphoid tissue, bone marrow myeloid, and
lymphoid cells, and peripheral blood lymphocytes, mono-
cytes, and neutrophils within 24hours of a single oral dose
[11]. Furthermore, CI-994 concentrations used in vitro were
in the same range as plasma and cerebrospinal ﬂuid concen-
trations of CI-994 achieved in vivo in preclinical and clinical
studies [10, 13, 33]. Collectively, these results demonstrate1:2 (2001)Induction of apoptosis in rat lymphocytes by CI-994 57
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Figure 5: Sub-G1 DNA content in rat peripheral blood lymphocytes exposed to CI-994 for 4 or 24hours. (A)Sub-G1 DNA content
quantitated by ﬂow cytometry and Hoechst 33342 stain. Mitogen (concanavalin A, 0.63µg/ml)was added to all lymphocyte cultures at
time zero. Data represent the mean ± SE of at least 4 individual experiments. ∗Signiﬁcantly different from control using Kruskal-Wallis one
way ANOVA on ranked data and Dunn’s post hoc test (p<0.05). Representative DNA histograms of (B) untreated rat peripheral blood
lymphocytes and (C)lymphocytes treated with 30 µM CI-994 for 24hours. R1 = gated sub-G1 DNA population.58 Michael J. Graziano et al. 1:2 (2001)
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Figure 6: DNA fragmentation in rat peripheral blood lympho-
cytes exposed to CI-994 for 24hours. Mitogen (concanavalin A,
0.63µg/ml)was added to all lymphocyte cultures at time zero.
DNA (0.6µg)was separated on a 1% agarose gel stained with ethid-
ium bromide. Arrows indicate molecular weight markers. Positive
control = 1µM staurosporine (lane 6).
that peripheral rat blood lymphocytes represent a toxicolog-
ically relevant model for studying the mechanism of CI-994
toxicity in vitro.
Concanavalin A was added to the culture media in the
present study since preliminary experiments showed that
it had a protective effect on untreated lymphocytes by sig-
niﬁcantly reducing the spontaneous incidence of apopto-
sis. However, even with the addition of concanavalin A, lit-
tle if any proliferation occurred over 24hours (≤4%). This
observation is consistent with a reported 24–28hours de-
lay in cell division in rat lymphocytes in culture with con-
canavalin A [34], and suggests that the induction of apopto-
sis by CI-994 occurred independently of cell proliferation.
The ability of CI-994 to induce apoptosis in nonprolifer-
ating lymphocytes was conﬁrmed by the results of several
supplemental assays in which mitogen was omitted from
the incubation mixture. The apoptotic effects of CI-994 on
nonproliferating lymphocytes is similar to that of topoiso-
merase inhibitors and opposite of cisplatin and 2-chloro-2 -
deoxyadenosine, the latter of which appear to only induce
apoptosis in dividing cells [35–38]. The effect of CI-994 on
nonproliferating cells is also consistent with the rapid loss
of peripheral blood lymphocytes following CI-994 adminis-
tration in vivo [11]. The majority of circulating lymphocytes
are considered long-lived and do not proliferate in the ab-
sence of antigenic stimulation [39–41]. Therefore, apoptotic
cell death is one possible mechanism by which circulating
lymphocytes may be depleted during in vivo exposure to CI-
994.
ApoptosisinducedbyCI-994doesnotoccurasrapidlyas
with other cytotoxic anticancer drugs. In the present study,
no apoptosis was observed in lymphocytes after 4hours
of exposure to CI-994. In contrast, a variety of anticancer
drugs, including topoisomerase inhibitors such as etopo-
side and camptothecin, can induce apoptosis in mouse and
rat thymocytes and in human HL60 leukemia cells within
2 to 4hours of incubation [38, 42–45]. Whether the de-
layed effects of CI-994 are due to different experimen-
tal conditions (e.g., use of rat lymphocytes in the present
study)or differences related to the mechanism of action
of CI-994 is unknown. Nonetheless, these results corre-
late with the inhibitory effect of CI-994 on cell cycle pro-
gression prior to the appearance of cytotoxicity in vitro
[46].
Although the mechanism of action of CI-994 has not yet
been deﬁned, it may be the same in both tumor cells and
normaltissuesinceCI-994wasalsoshowntoinduceapopto-
sis in HL60 leukemia cells [47]. The mechanism of apoptosis
was not investigated in this study but previous reports sug-
gest that it may be initiated by either inhibition of a 16kDa
nuclear phosphoprotein or an increase in histone acetyla-
tion [8, 9]. In both studies, these targets were modulated
within 2hours of exposure and thus represent the earliest ef-
fects detected following CI-994 treatment in vitro. Whether
inhibition of the 16kDa nuclear phosphoprotein or an in-
crease in histone acetylation is the initiating event leading
to cell death induced by CI-994 has not been established. In
HL60 cells, CI-994-induced apoptosis involves activation of
caspase-3andcleavageofpoly(ADP-ribose)polymerase[47].
Sincecaspase-3isadownstreameffectorcaspase,itispossible
that other caspases may also be involved in CI-994-induced
apoptosis.
Levels of PARP, which can recognize and bind to DNA
strand-breaks [48, 49], appeared to be increased in HL60
cellsfollowingexposureto3µMCI-994[47].Itisnotknown
whether this latter observation is indicative of DNA damage
at low concentrations of CI-994 or represents a characteris-
tic burst in PARP activity early in the apoptotic process [50].
The precise role of DNA damage in CI-994 cytotoxicity has
not been completely investigated but in vitro studies with
the deacetylated analogue, dinaline, showed that cytotoxic-
ity in L1210 leukemia cells could not be reversed by purines,
pyrimidines, or reduced folates [51]. There were also no di-
recteffectsonribonucleotidephosphatepoolsorDNA,RNA,
or lipid synthesis. Since dinaline and CI-994 have equivalent
antitumor activity [1, 4, 46], these results suggest that CI-
994 does not act as an antimetabolite, nor does it directly ef-
fectmacromolecularsynthesis.However,inhibitionofCI-994
and dinaline on DNA synthesis measured by [3H]thymidine
incorporationhasbeenobservedinratperipheralbloodlym-
phocytes and human colon carcinoma SW707 cells [11, 52].
In summary, CI-994 induced apoptosis in rat peripheral
blood lymphocytes in a concentration-dependent manner.
Apoptosis was conﬁrmed by morphological and biochemical
changesincludingmembraneblebbing,chromatincondensa-
tion,DNAfragmentation,andexternalizationof PS.Necrosis
was not detected to any signiﬁcant extent. These results show
that apoptosis is the primary mode of cell death in rat lym-
phocytes exposed to CI-994 in vitro.1:2 (2001)Induction of apoptosis in rat lymphocytes by CI-994 59
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Figure 7: Externalization of phosphatidyl serine (PS)in rat peripheral blood lymphocytes exposed to CI-994 for 4 or 24hours. (A)Exter-
nalized PS in the cellular membrane was detected by ﬂow cytometry and annexin V-FITC stain. Mitogen (concanavalin A, 0.63µg/ml)was
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